Compare Citius Pharmaceuticals Inc (CTXR) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Nasdaq100 ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Nasdaq100 ETF trades at $751.27 (market cap $506.92B). The key difference: Nasdaq100 ETF is far larger — about 37218.8× Citius Pharmaceuticals Inc's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Nasdaq100 ETF for 162 Days on average.
| CTXR | QQQ | |
|---|---|---|
Market Cap | $13.62M | $506.92B |
Volume | 132,438 | 48,326,518 |
Sector | Health | — |
52-Week High | $1.82 | $759.66 |
52-Week Low | $0.48 | $558.34 |
Typical Hold Time | 17 Days | 162 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
QQQ trades at $747.64, down 1.33% today amid mixed market signals. Technical analysis shows a bullish trend with strong moving average support, while oscillators remain neutral. Analyst sentiment is divided with a 50/50 split between buy and sell recommendations. The ETF maintains exposure to leading technology stocks but faces valuation concerns as AI-driven enthusiasm pushes multiples higher.
The outlook remains cautiously optimistic given QQQ's tech concentration and AI growth potential, though elevated valuations and interest rate sensitivity present near-term risks. Long-term growth prospects appear solid, but investors should monitor earnings sustainability and Fed policy impacts on tech valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
